Table of Contents Author Guidelines Submit a Manuscript
International Journal of Medicinal Chemistry
Volume 2017, Article ID 7386125, 12 pages
https://doi.org/10.1155/2017/7386125
Research Article

Design, Synthesis, and Cytotoxicity Evaluation of Novel Griseofulvin Analogues with Improved Water Solubility

1Department of Medicinal Chemistry, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt
2Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt

Correspondence should be addressed to Atef A. Abdel-Hafez; ge.ude.nua@feta

Received 29 August 2017; Revised 12 October 2017; Accepted 23 October 2017; Published 7 December 2017

Academic Editor: Hussein El-Subbagh

Copyright © 2017 Ahmed K. Hamdy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. E. Oxford, H. Raistrick, and P. Simonart, “Studies in the biochemistry of micro-organisms: griseofulvin, C17H17O6Cl, a metabolic product of Penicillium griseo-fulvum Dierckx,” Biochemical Journal, vol. 33, no. 2, pp. 240–248, 1939. View at Google Scholar
  2. J. C. Gentles, “Experimental ringworm in guinea pigs: oral treatment with griseofulvin,” Nature, vol. 182, no. 4633, pp. 476-477, 1958. View at Publisher · View at Google Scholar · View at Scopus
  3. D. I. Williams, R. H. Marten, and I. Sarkany, “Oral treatment of ringworm with griseofulvin,” The Lancet, vol. 272, no. 7058, pp. 1212-1213, 1958. View at Publisher · View at Google Scholar · View at Scopus
  4. A. B. Petersen, N. S. Andersen, G. Konotop et al., “Synthesis and formulation studies of griseofulvin analogues with improved solubility and metabolic stability,” European Journal of Medicinal Chemistry, vol. 130, pp. 240–247, 2017. View at Publisher · View at Google Scholar · View at Scopus
  5. V. Mauro, D. Carette, R. Pontier-Bres et al., “The anti-mitotic drug griseofulvin induces apoptosis of human germ cell tumor cells through a connexin 43-dependent molecular mechanism,” Apoptosis, vol. 18, no. 4, pp. 480–491, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. Y.-S. Ho, J.-S. Duh, J.-H. Jeng et al., “Griseofulvin potentiates antitumorigenesis effects of nocodazole through induction of apoptosis and G2/M cell cycle arrest in human colorectal cancer cells,” International Journal of Cancer, vol. 91, no. 3, pp. 393–401, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. D. Panda, K. Rathinasamy, M. K. Santra, and L. Wilson, “Kinetic suppression of microtubule dynamic instability by griseofulvin: implications for its possible use in the treatment of cancer,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 102, no. 28, pp. 9878–9883, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Kawamura, A. B. Fielding, N. Kannan et al., “Identification of novel small molecule inhibitors of centrosome clustering in cancer cells,” Oncotarget , vol. 4, no. 10, pp. 1763–1776, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Kim, P. Alpmann, S. Blaum-Feder et al., “In vivo efficacy of griseofulvin against multiple myeloma,” Leukemia Research, vol. 35, no. 8, pp. 1070–1073, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. A. R. Chaudhuri and R. F. Ludueña, “Griseofulvin: interaction with normal and subtilisin-treated tubulin,” Drug Development Research, vol. 53, no. 1, pp. 44–49, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. R. A. B. Keates, “Griseofulvin at low concentration inhibits the rate of microtubule polymerization in vitro,” Biochemical and Biophysical Research Communications, vol. 102, no. 2, pp. 746–752, 1981. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Rathinasamy, B. Jindal, J. Asthana, P. Singh, P. V. Balaji, and D. Panda, “Griseofulvin stabilizes microtubule dynamics, activates p53 and inhibits the proliferation of MCF-7 cells synergistically with vinblastine,” BMC Cancer, vol. 10, article no. 213, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. B. Rebacz, T. O. Larsen, M. H. Clausen et al., “Identification of griseofulvin as an inhibitor of centrosomal clustering in a phenotype-based screen,” Cancer Research, vol. 67, no. 13, pp. 6342–6350, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. N. Korzeniewski, M. Hohenfellner, and S. Duensing, “The centrosome as potential target for cancer therapy and prevention,” Expert Opinion on Therapeutic Targets, vol. 17, no. 1, pp. 43–52, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Milunović-Jevtić, P. Mooney, T. Sulerud, J. Bisht, and J. C. Gatlin, “Centrosomal clustering contributes to chromosomal instability and cancer,” Current Opinion in Biotechnology, vol. 40, pp. 113–118, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. M. H. Rønnest, M. S. Raab, S. Anderhub et al., “Disparate SAR data of griseofulvin analogues for the dermatophytes Trichophyton mentagrophytes, T. rubrum, and MDA-MB-231 cancer cells,” Journal of Medicinal Chemistry, vol. 55, no. 2, pp. 652–660, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. M. H. Rønnest, B. Rebacz, L. Markworth et al., “Synthesis and structure—activity relationship of griseofulvin analogues as inhibitors of centrosomal clustering in cancer cells,” Journal of Medicinal Chemistry, vol. 52, no. 10, pp. 3342–3347, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. M. S. Raab, I. Breitkreutz, S. Anderhub et al., “GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo,” Cancer Research, vol. 72, no. 20, pp. 5374–5385, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. L. J. Fischer and S. Riegelman, “Absorption and activity of some derivatives of Griseofulvin,” Journal of Pharmaceutical Sciences, vol. 56, no. 4, pp. 469–476, 1967. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Walker, “Process of preparing griseofulvic acid,” Tech. Rep. 3,102,122, 1963. View at Google Scholar
  21. L. C. J. Dorssers, S. Van Der Flier, A. Brinkman et al., “Tamoxifen resistance in breast cancer elucidating mechanisms,” Drugs, vol. 61, no. 12, pp. 1721–1733, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. V. Molecular operating Enviroment (MOE), Chemical Computing group Inc., Montreal, Quebec, Canada, http://www.chemcomp.com.
  23. ACD/I-Lab, https://ilab.acdlabs.com/iLab2/index.php.
  24. M. H. Clausen, A. Kramer, T. O. Larsen, and B. Leber, “Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering,” PatentWO 2009000937, 2008. View at Google Scholar
  25. P. Skehan, R. Storeng, D. Scudiero et al., “New colorimetric cytotoxicity assay for anticancer-drug screening,” Journal of the National Cancer Institute, vol. 82, no. 13, pp. 1107–1112, 1990. View at Publisher · View at Google Scholar · View at Scopus
  26. T. C. Chou, “Theoretical basis, experimental design and computerized simulation of synergism and antagonism in drug combination studies,” Pharmacological Reviews, vol. 58, no. 3, pp. 621–681, 2006. View at Publisher · View at Google Scholar